Business Case

Companion diagnostic strategy for launch of novel biomarker-driven oncology drug

Our client, a top biopharma company, was expected to launch a novel biomarker-driven oncology drug and needed to devise a strategy to ensure the biomarker/companion diagnostic (CDx) testing would not be a barrier to drug uptake. LSC was able to develop a CDx situation analysis, including key testing challenges, and devise specific imperatives to overcome these specific challenges and enable easy patient access to the CDx test. Post-launch, testing rates and drug revenue met forecasted expectations.